Farnesyltransferase inhibitors:a cell signalling approach to the design of efficacious anticancer agents

Bibliography

• PARKER SL, TONG T, BOLDEN S, WINGO PA: Cancer statistics, 1997. CA-A Cancer Journal for Clinicians (1997) 47(1)5–27.
   PubMed Web of Science ®Google Scholar
• REISS Y, GOLDSTEIN JL, SEABRA MC, CASEY PJ, BROWN MS: Inhibition of purified p21 Ras farnesyl: protein transferase by cys-AAX tetrapeptides. Cell (1990) 62:81–88.
   PubMed Web of Science ®Google Scholar
• KATO K, COX AD, HISAKA MM, et al.: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA (1992) 89:6403–6407.
   PubMed Web of Science ®Google Scholar
• •Provided early evidence for the role of farnesylation in transformation thereby serving as a rationale for pursuing FTIs as anticancer drugs.
   Google Scholar
• LEONARD DM: Ras famesyltransferase: a new therapeutic target. J. Med. Chem. (1997)40:2971–2990.
   PubMed Web of Science ®Google Scholar
• •A comprehensive and recent review of the diverse array of FTIs reported in the literature.
   Google Scholar
• GARCIA AM, ROWELL C, ACKERMANN K, KOWALCZYK JJ, LEWIS MD: Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. (1993) 268:18415–18418.
   PubMed Web of Science ®Google Scholar
• NAGASU T, YOSHIMATSU K, ROWELL C, LEWIS MD, GARCIA AM: Inhibition of human tumour xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res. (1995) 55:5310–5314.
   PubMed Web of Science ®Google Scholar
• MANNE V, YAN N, CARBONI JM, et al.: Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene (1995) 10:1763–1779.
   PubMed Web of Science ®Google Scholar
• HUNT JT, LEE VG, LEFTHERIS B, et al.: Potent cell active, non-thiol tetrapeptide inhibitors of farnesyl transferase. J. Med. Chem. (1996) 39:353–358.
   PubMed Web of Science ®Google Scholar
• JAMES GL, GOLDSTEIN JL, BROWN MS, et al.: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (1993) 260:1937–1942.
   PubMed Web of Science ®Google Scholar
• VOGT A, QIAN Y, BLASKOVICH MA, et al.: A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem. (1995) 270:660–664.
   PubMed Web of Science ®Google Scholar
• SUN J, QIAN Y, HAMILTON AD, SEBTI SM: Ras CAAX peptidomimetic FTI276 selectively blocks tumour growth in nude mice of a human lung carcinoma with k-ras mutation and p53 deletion. Cancer Res. (1995) 55:4243–4247.
   PubMed Web of Science ®Google Scholar
• •Demonstration of significant in vivo activity against k-ras mutated human tumour xenografts.
   Google Scholar
• LERNER EC, QIAN Y, BLASKOVICH MA, et al.: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. (1995) 270:26802–26806.
   PubMed Web of Science ®Google Scholar
• KOHL NE, MOSSER SD, DESOLMS SJ, et al.: Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 260:1934–1937.
   PubMed Web of Science ®Google Scholar
• KOHL NE, WILSON FR, MOSSER SD, et al.: Protein farnesyltransferase inhibitors block the growth of Ras-dependent tumours in nude mice. Proc. Natl. Acad. Sci. USA (1994) 91:9141–9145.
   PubMed Web of Science ®Google Scholar
• KOHL NE, OMER CA, CONNER MW, et al.: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. (1995) 1:792–797.
   PubMed Web of Science ®Google Scholar
• •Actual tumour regressions observed in this study rather than cytostasis.
   Google Scholar
• MCNAMARA DJ, DOBRUSIN E, LEONARD DM, et al.: C-terminal modification of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice. J. Med. Chem. (1997) 40:3319–3322.
   PubMed Web of Science ®Google Scholar
• •Demonstration of significant anticancer activity against tumour xenografts for a class of FPP-competitive FTIs.
   Google Scholar
• BISHOP WR, BOND R, PETRIN J, et al.: Novel tricyclic inhibitors of farnesyl protein transferase. J. Biol. Chem. (1995) 270:30611–30618.
   PubMed Web of Science ®Google Scholar
• Bowman WC, Fitzgerald JD, Taylor JB (Eds.), Ashley Publications Ltd., London (1996) :219–239.
   Google Scholar
• •An overview of the anticancer drug potential of farnesyltransferase inhibitors along with the special challenges accompanying their development.
   Google Scholar
• BARINAGA M: From bench top to bedside. Science (1997) 278:1036–1039.
   PubMed Web of Science ®Google Scholar
• WHYTE DB, KIRSCHMEIER P, HOCKENBERRY TN, et al.: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. (1997) 272:14459–14464.
   PubMed Web of Science ®Google Scholar
• LIU M, CHEN P, LEE S, et al.: SCH59228, a novel tricyclic inhibitor of farnesylprotein transferase, potently blocks the growth of Ras transformed fibroblasts and human tumour cell lines in nude mice. Proc. Am. Assoc. Cancer Res. (1997) 38:349, Abstract 2341.
   Google Scholar
• PRZYBRANOWSKI SA, ELLIOTT WL, LEONARD DN et al.: In vivo evaluation of histidine-(N-benzylglycinamides) as inhibitors of Ras farnesyltransferase. Proc. Am. Assoc. Cancer Res. (1997) 38:350, Abstract 2344.
   Google Scholar
• LEONARD DM, SHULER KR, POULTER CJ, et al.: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit Ras farnesyltransferase. J. Med. Chem. (1997) 40:192–200.
   PubMed Web of Science ®Google Scholar
• JAMES GL, GOLDSTEIN JL, BROWN MS: Polylysine and CVIM sequences of KrasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. Proc. Natl. Acad. Sci. USA (1996) 93:4454–4458.
   PubMed Web of Science ®Google Scholar
• •Provides evidence for Kras4B being geranylgeranylated.
   Google Scholar
• COX AD, DER CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras Biochim. Biophys. Acta (1997) 1333:F51–F71.
   PubMed Web of Science ®Google Scholar
• ••A provocative review summarising the biological consequences of FTI treatment and thepotential role of non-Ras targets.
   Google Scholar
• FOSTER R, HU KQ, LU Y, et al.: Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. Mol. Cell. Biol. (1996) 16:2689–2699.
   PubMed Web of Science ®Google Scholar
• CLARK GJ, KINCH MS, ROGERS-GRAHAM K, et al.: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. (1997) 272:10608–10615.
   PubMed Web of Science ®Google Scholar
• CROWELL PL, CATES CA, BURKE Y D, et al.: Prenylation of novel oncogenic human PTP CAAX protein tyrosine phosphatases. Proc. Am. Assoc. Cancer Res. (1996) 37:576.
   Google Scholar
• BERNHARD EJ, KAO G, COX AD, et al.: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed Rat embryo fibroblasts. Cancer Res. (1996) 56:1727–1730.
   PubMed Web of Science ®Google Scholar
• •Cell culture studies combining an FTI with radiation.
   Google Scholar